Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2016 - 2025)
Perspective Therapeutics (CATX) reported Asset Writedowns and Impairment of $10.0 million for Q4 2025, up 22627.27% sequentially from $44000.0 in Q3 2024.
Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2016 - 2025) Analysis & Trends
Perspective Therapeutics (CATX) has 5 years of Asset Writedowns and Impairment data on file, last reported at $10.0 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2025 stood at $10.4 million (up 1452.4% YoY), and the FY2025 full-year result was $10.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment advanced to $10.0 million in Q4 2025, from $44000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $10.0 million in Q4 2025 to a low of $44000.0 in Q3 2024.
- A 3-year average of $2.2 million and a median of $298000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 85.23% in 2024, while the deepest fall reached 85.23% in 2024.
- Tracing CATX's Asset Writedowns and Impairment over 3 years: stood at $326000.0 in 2023, then slumped by 86.5% to $44000.0 in 2024, then soared by 22627.27% to $10.0 million in 2025.
- Business Quant data shows CATX's Asset Writedowns and Impairment at $10.0 million in Q4 2025, $44000.0 in Q3 2024, and $326000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.00 Mn |
| Dec 31, 2025 | 10.00 Mn |
| Sep 30, 2024 | 44,000.00 |
| Sep 30, 2024 | 44,000.00 |
| Dec 31, 2023 | 326,000.00 |
| Dec 31, 2023 | 326,000.00 |
| Sep 30, 2023 | 298,000.00 |
| Sep 30, 2023 | 298,000.00 |
| Jun 30, 2023 | 298,000.00 |
| Jun 30, 2023 | 298,000.00 |
| Jun 30, 2017 | -4,000.00 |
| Jun 30, 2017 | -4,000.00 |
| Mar 31, 2016 | 72,000.00 |
| Mar 31, 2016 | 72,000.00 |